chitosan has been researched along with Non-alcoholic Fatty Liver Disease in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, H; Li, T; Mao, X; Zhan, B | 1 |
| Peng, Y; Qiu, L; Xie, P | 1 |
| Bai, Y; Cao, H; Che, Q; Chen, J; Feng, J; Guo, J; He, J; Liu, Y; Su, Z | 1 |
| Arya, JK; Kumar, R; Rizvi, SI | 1 |
| Bai, Y; Cao, H; Che, Q; Feng, J; Guo, J; Su, Z; Zhang, J | 1 |
| Liu, L; Pei, X; Sun, W; Tao, W; Wang, G; Wang, M; Xiao, Z | 1 |
| Eguchi, F; Hamaya, T; Kurihara, S; Miyazawa, N; Yoshimoto, H | 1 |
| Fan, Q; Feng, N; Huang, P; Jiang, Z; Li, Z; Liang, J; Liu, J; Liu, Y; Wang, Z; Yan, F | 1 |
| Chen, W; Fan, J; Hao, Q; Jin, X; Ju, D; Liu, H; Luan, J; Mei, X; Tang, S; Wu, Z; Zai, W; Zhang, X | 1 |
| Duan, X; Gao, Y; Hu, H; Liu, W; Liu, Y; Lyu, Q; Pan, C; Qi, LW; Qian, M; Wang, L; Wang, S | 1 |
| Geng, N; Jiang, M; Li, XJ; Wang, J; Xin, YN; Xuan, SY | 1 |
| Liu, X; Shen, J; Song, T; Sun, Z; Wang, Q; Yang, F; Zeng, A | 1 |
12 other study(ies) available for chitosan and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Chitosan oligosaccharide attenuates hepatic steatosis in HepG2 cells via the activation of AMP-activated protein kinase.
Topics: AMP-Activated Protein Kinases; Chitosan; Fatty Acids; Hep G2 Cells; Humans; Lipids; Non-alcoholic Fatty Liver Disease; Oligosaccharides | 2022 |
Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1.
Topics: Animals; Chitosan; Diet, High-Fat; Exenatide; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oligosaccharides; Sirtuin 1; Ursodeoxycholic Acid | 2022 |
Marine Chitooligosaccharide Alters Intestinal Flora Structure and Regulates Hepatic Inflammatory Response to Influence Nonalcoholic Fatty Liver Disease.
Topics: Animals; Chitosan; Diet, High-Fat; Gastrointestinal Microbiome; Lipopolysaccharides; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oligosaccharides | 2022 |
Chitosan reduces inflammation and protects against oxidative stress in a hyperlipidemic rat model: relevance to nonalcoholic fatty liver disease.
Topics: Adiponectin; Animals; Antioxidants; Chitosan; Cholesterol; Cytokines; Diet, High-Fat; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Leptin; Lipid Metabolism; Lipids; Liver; Male; NF-kappa B; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rats; Rats, Wistar; Triglycerides | 2022 |
Ameliorating the effect and mechanism of chitosan oligosaccharide on nonalcoholic fatty liver disease in mice.
Topics: Animals; Chitosan; Diet, High-Fat; Fatty Acids, Volatile; Humans; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oligosaccharides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Ribosomal, 16S; TOR Serine-Threonine Kinases | 2023 |
Chitosan Oligosaccharide Attenuates Nonalcoholic Fatty Liver Disease Induced by High Fat Diet through Reducing Lipid Accumulation, Inflammation and Oxidative Stress in C57BL/6 Mice.
Topics: Animals; Chitosan; Cytokines; Diet, High-Fat; Inflammation; Lipid Metabolism; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Non-alcoholic Fatty Liver Disease; Oligosaccharides; Oxidative Stress | 2019 |
Improvement of Diet-induced Obesity by Ingestion of Mushroom Chitosan Prepared from Flammulina velutipes.
Topics: Adipocytes; Administration, Oral; Animals; Anti-Obesity Agents; Chitosan; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Flammulina; Lipolysis; Male; Mice, Inbred ICR; Non-alcoholic Fatty Liver Disease; Obesity; Phytotherapy; Weight Gain | 2018 |
Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD.
Topics: Administration, Oral; Animals; Biological Availability; Biological Transport; Caco-2 Cells; Chitosan; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Female; Hep G2 Cells; Humans; Lactic Acid; Lipids; Liver; Male; Mice; Mice, Transgenic; Molecular Structure; Nanoparticles; Non-alcoholic Fatty Liver Disease; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Silymarin; Surface Properties | 2018 |
Targeted Interleukin-22 Gene Delivery in the Liver by Polymetformin and Penetratin-Based Hybrid Nanoparticles to Treat Nonalcoholic Fatty Liver Disease.
Topics: Animals; Cell-Penetrating Peptides; Chitosan; Diet, High-Fat; Disease Models, Animal; Gene Transfer Techniques; Hep G2 Cells; Humans; Interleukin-22; Interleukins; Male; Metformin; Mice; Mice, Inbred C57BL; Nanoparticles; Non-alcoholic Fatty Liver Disease | 2019 |
Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice.
Topics: Administration, Oral; Animals; Chitosan; Diet, High-Fat; Disease Models, Animal; Drug Evaluation, Preclinical; Fatty Acids, Nonesterified; Gastrointestinal Microbiome; Humans; Lipid Metabolism; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Oligosaccharides; Protective Agents; Triglycerides | 2019 |
[Effect of chitooligosaccharide on hepatic triglyceride metabolism and related mechanisms].
Topics: Animals; Chitin; Chitosan; Diet, High-Fat; Hepatocytes; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oligosaccharides; Random Allocation; Rats; Sterol Regulatory Element Binding Protein 1; Triglycerides | 2016 |
Synthesis of carboxymethylated and quaternized chitosans and their therapeutic effect on nonalcoholic Fatty liver disease.
Topics: Animals; Chitosan; Diet, High-Fat; Fatty Liver; Lipid Metabolism; Male; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Receptors, LDL; Structure-Activity Relationship | 2011 |